CS-3150, a Novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced Hypertensive Rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 3, 2016, Pages 548-557

  Arai, Kiyoshi ^a   Morikawa, Yuka ^a   Ubukata, Naoko ^a   Tsuruoka, Hiroyuki ^a   Homma, Tsuyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYETHYL) 4 METHYL N [4 (METHYLSULFONYL)PHENYL] 5 [2 (TRIFLUOROMETHYL)PHENYL] 1H PYRROLE 3 CARBOXAMIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; INTERLEUKIN 6; MINERALOCORTICOID ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CS-3150; DEOXYCORTICOSTERONE ACETATE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PYRROLE DERIVATIVE; SALT INTAKE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULOSCLEROSIS; HEART PROTECTION; HYPERTENSION; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INJURIES; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; SALT INTAKE;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE ACETATE; GENE EXPRESSION REGULATION; HYPERTENSION; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ORGAN SIZE; PYRROLES; RATS; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY; SULFONES;

EID: 84983742558     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.234765     Document Type: Article

References (52)

1. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, and Ritz E (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833-2842.
2. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, and Sada T (2015) Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol 761:226-234.
3. Barrett KV, McCurley AT, and Jaffe IZ (2013) Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol 40:902-909.
4. Benigni A, Morigi M, and Remuzzi G (2010) Kidney regeneration. Lancet 375: 1310-1317.
5. Beswick RA, Dorrance AM, Leite R, and Webb RC (2001) NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38:1107-1111.
6. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, and McMahon EG (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791-1800.
7. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, and Kamper AL (2011) Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 6: E26904.
8. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, and Chatziantoniou C (2003) Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14:1132-1144.
9. Brem AS, Morris DJ, and Gong R (2011) Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis 58:471-479.
10. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, and Fogo AB (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58:1219-1227.
11. Calhoun DA and White WB (2008) Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2: 462-468.
12. Chabert PR, Guelpa-Decorzant C, Riondel AM, and Vallotton MB (1984) Effect of spironolactone on electrolytes, renin, ACTH and corticosteroids in the rat. J Steroid Biochem 20 (6A):1253-1259.
13. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, and Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839-845.
14. Choi S, Park M, Kim J, Hwang S, Park S, and Lee Y (2009) The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev 18:521-529.
15. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, Hamid MR, Tamiya T, Nishiyama A, and Hitomi H (2008) Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 314:3654-3662.
16. Drawz P and Rahman M (2015) Chronic kidney disease. Ann Intern Med 162: ITC1-ITC16.
17. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, and Mussap M (2006) Renal protection in diabetes: Role of glycemic control. J Am Soc Nephrol 17(4, Suppl2) S86-S89.
18. Funder JW (1995) Mineralocorticoid receptors and hypertension. J Steroid Biochem Mol Biol 53:53-55.
19. Gaede P, Tarnow L, Vedel P, Parving HH, and Pedersen O (2004) Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19: 2784-2788.
20. Hovind P, Rossing P, Tarnow L, Smidt UM, and Parving HH (2001) Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60:277-283.
21. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, Hirakata H, and Iida M (2009) Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75:147-155.
22. Jiménez W, Martínez-Pardo A, Arroyo V, Gaya J, and Rivera F (1988) Effect of spironolactone on the renin- Aldosterone system in rats. Rev Esp Fisiol 44:257-263.
23. Klahr S (1999) Mechanisms of progression of chronic renal damage. J Nephrol 12 (Suppl2):S53-S62.
24. Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, and Hilgers KF (2008) Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrol Dial Transplant 23:3456-3463.
25. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, and Fogo AB (2000) Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58:2425-2436.
26. Macisaac RJ, Ekinci EI, and Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2, Suppl2)S39-S62.
27. Maeshima A, Yamashita S, and Nojima Y (2003) Identification of renal progenitorlike tubular cells that participate in the regeneration processes of the kidney. J Am Soc Nephrol 14:3138-3146.
28. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, et al. (2012) Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18: 1429-1433.
29. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, and Toto RD (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20: 2641-2650.
30. Muller OG, Parnova RG, Centeno G, Rossier BC, Firsov D, and Horisberger JD (2003) Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na1 and K1. J Am Soc Nephrol 14:1107-1115.
31. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, et al. (2005) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46:1039-1045.
32. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, et al. (2005) Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45:710-716.
33. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, et al. (2004) Possible contributions of reactive oxygen species and mitogen- Activated protein kinase to renal injury in aldosterone/saltinduced hypertensive rats. Hypertension 43:841-848.
34. Oki K, Gomez-Sanchez EP, and Gomez-Sanchez CE (2012) Role of mineralocorticoid action in the brain in salt-sensitive hypertension. Clin Exp Pharmacol Physiol 39: 90-95.
35. Patni H, Mathew JT, Luan L, Franki N, Chander PN, and Singhal PC (2007) Aldosterone promotes proximal tubular cell apoptosis: Role of oxidative stress. Am J Physiol Renal Physiol 293:F1065-F1071.
36. Phillips A, Janssen U, and Floege J (1999) Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res 22: 81-97.
37. Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, and Cook HT (2006) Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24: 2448-2455.
38. Rafiq K, Nishiyama A, Konishi Y, Morikawa T, Kitabayashi C, Kohno M, Masaki T, Mori H, Kobori H, and Imanishi M (2014) Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats. PLoS One 9:e107853.
39. Rahmouni K, Sibug RM, De Kloet ER, Barthelmebs M, Grima M, Imbs JL, and De Jong W (2002) Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension. Eur J Pharmacol 436: 207-216.
40. Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, and Remuzzi G (2006) ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 69: 1124-1130.
41. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, and Young MJ (2014) Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/saltmediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 63:1033-1040.
42. Romagnani P, Lasagni L, and Remuzzi G (2013) Renal progenitors: An evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol 9:137-146.
43. Rossing K, Christensen PK, Hovind P, and Parving HH (2005) Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 48:2241-2247.
44. Sato A, Hayashi K, and Saruta T (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18:44-49.
45. Seifi B, Kadkhodaee M, Karimian SM, Zahmatkesh M, Xu J, and Soleimani M (2010) Evaluation of renal oxidative stress in the development of DOCA-salt induced hypertension and its renal damage. Clin Exp Hypertens 32:90-97.
46. Shibata S, Nagase M, Yoshida S, Kawachi H, and Fujita T (2007) Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension 49: 355-364.
47. Shuvy M, Nyska A, Beeri R, Abedat S, Gal-Moscovici A, Rajamannan NM, and Lotan C (2011) Histopathology and apoptosis in an animal model of reversible renal injury. Exp Toxicol Pathol 63:303-306.
48. Siragy HM and Xue C (2008) Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 93:817-824.
49. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, et al. (2006) Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17:2193-2201.
50. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, Silva LF, and Zatz R (2009) Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 75:72-79.
51. Uehara Y, Kawabata Y, Shirahase H, Wada K, Hashizume Y, Morishita S, Numabe A, and Iwai J (1993) Oxygen radical scavengers and renal protection by indapamide diuretic in salt-induced hypertension of Dahl strain rats. J Cardiovasc Pharmacol 22 (Suppl6):S42-S46.
52. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, and Remuzzi G (2010) Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 299:F1203-F1211.